Biogen Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +20

Biogen Inc. (BIIB): An Oversold Large Cap Stock To Buy Now

📊 Biogen Inc. (NASDAQ: BIIB) is ranked 2nd on a list of oversold large-cap stocks compiled by Insider Monkey.

🏥 The company recently reported positive Phase 3 results for dapirolizumab pegol in treating systemic lupus erythematosus (SLE).

🧬 A higher-dose regimen of nusinersen for spinal muscular atrophy (SMA) showed clinical benefits and slowed neurodegeneration in recent trials.

💉 Felzartamab received FDA Breakthrough Therapy Designation for treating late antibody-mediated rejection in kidney transplant patients.

📉 The article notes Biogen is considered oversold based on a Finviz screener filtering for significant YTD declines and forward P/E ratios between 5x to 15x.

🤖 Despite Biogen's clinical wins, the author argues AI stocks offer greater promise for higher returns within a shorter timeframe.

📈 The analysis suggests investors looking for cheap AI exposure should check separate reports rather than focusing on Biogen.

🗓️ Phase 3 trials for felzartamab in other rare immune-mediated diseases are planned for 2025.

🏛️ The selection methodology prioritizes stocks widely held by institutional investors with favorable hedge fund sentiment.

📰 The article is part of a newsletter strategy that claims to beat its benchmark by 150 percentage points since May 2014.

Bullish Signals
  • Biogen recently achieved positive results from the Phase 3 PHOENYCS GO trial for dapirolizumab pegol, meeting primary goals and demonstrating reduced disease activity in moderate-to-severe systemic lupus erythematosus.
  • The company's higher-dose nusinersen regimen for spinal muscular atrophy showed clinical benefits in both previously treated and treatment-naive individuals, indicating a slowdown in neurodegeneration.
  • Felzartamab has received FDA Breakthrough Therapy Designation for treating late antibody-mediated rejection in kidney transplant patients, addressing a major cause of transplant failure.
  • Biogen is included in a curated list of oversold large-cap stocks identified by institutional investors and hedge funds using specific valuation filters.
Risk Factors
  • The article explicitly ranks Biogen second on the investment list, stating that the author's conviction lies more with Artificial Intelligence stocks which are viewed as having greater promise for delivering higher returns.
  • The analysis suggests that if investors are looking for AI stocks trading at less than 5 times earnings, they should look elsewhere rather than focusing on Biogen.
Full Analysis
This article evaluates Biogen Inc. (NASDAQ: BIIB) as an oversold large-cap stock within a broader list of investment opportunities compiled by Insider Monkey. The analysis places the biopharmaceutical company in the context of recent Federal Reserve rate cuts and general market optimism, noting that while macroeconomic factors support equity markets, specific sector performance varies. Biogen is highlighted for its focus on serious neurological and rare diseases, including multiple sclerosis, Alzheimer's, and ALS. The article details three significant recent clinical milestones: positive Phase 3 results for dapirolizumab pegol in systemic lupus erythematosus (SLE), successful higher-dose nusinersen trials for spinal muscular atrophy (SMA) showing slowed neurodegeneration, and FDA Breakthrough Therapy Designation for felzartamab in kidney transplant rejection. Despite these positive clinical developments, the article ranks Biogen second on its list of oversold stocks. The author explicitly states that conviction lies more heavily with Artificial Intelligence stocks, which are viewed as having greater promise for delivering higher returns over a shorter timeframe. Consequently, readers seeking AI exposure at low valuations are directed to separate reports rather than focusing on Biogen. The piece concludes by promoting the Insider Monkey newsletter strategy, which claims to outperform the market by imitating top hedge fund picks. It notes that the specific methodology for selecting oversold stocks involves filtering for significant year-to-date declines and forward P/E ratios between 5x and 15x, followed by institutional ownership analysis.